Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRM-359
- Development stage
- Unknown
- Lead developer
- Tremeau Pharmaceuticals
- Modality
- Small Molecules
01
Overview
**TRM-359** is a small molecule drug developed by Tremeau Pharmaceuticals, Inc. for the treatment of **pain** in the **nervous system diseases** therapeutic area. It is currently in **early Phase 1** clinical development, representing an investigational non-opioid analgesic candidate aimed at addressing unmet needs in pain management.[1][5]
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on TRM-359.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRM-359.